Bruce G. Haffty, M.D., FACR, FASTRO, FASCO is Associate Vice Chancellor, Cancer Programs, Rutgers Biomedical Health Sciences, Rutgers Cancer Institute of New Jersey, Professor and Chairman of Radiation Oncology, Rutgers-Robert Wood Johnson Medical School, New Jersey Medical School. His medical school, internship and residency training was at Yale School of Medicine. He spent the majority of his academic career at Yale, where he was Professor of Therapeutic Radiology, residency program director from 1992 through 2004, Vice Chairman and Clinical Director from 2002-2005. He moved to Rutgers Cancer Institute of New Jersey in 2005.
Dr. Haffty has a long and successful record in clinical and translational research in radiation oncology. He has coauthored a number of national clinical trials papers in high impact journals. He is currently co-investigator on several national clinical trials through the NRG and Alliance cooperative groups. He has published over 400 peer-reviewed articles, 30 book chapters, and numerous editorials and letters. He is consistently listed as one of the country’s leading physicians and best doctors through national registries.
In addition to a busy clinical practice, Dr. Haffty has served on numerous national committees related to research and education in breast cancer and radiation oncology. He is a Past President of the American Radium Society, past Chairman of the Residency Review Committee in Radiation Oncology, past President of the American Board of Radiology, and past President and Past Chairman of the Board of ASTRO. He currently serves as Deputy Editor of the Journal of Clinical Oncology and President-Elect of RSNA.
Dr. Haffty enjoys time with his loving wife, Kathy, their family. Lauren and her Husband Rob and their 3 children Genevieve, Matthew and Maeve; Sarah and her Husband Chris; Brian and his wife Keri, and their recent child Carter.
For more than 100 years, The American Cancer Society has been leading the fight to end cancer. With your support, we have helped usher in an era where more people survive cancer than ever before. By translating our research findings into action, we've seen a 20% decline in US cancer death rates since the early 1990s.